Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · NBIX · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
26
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Neurocrine Biosciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
NBIX insider buying and selling by quarter
NBIX insider selling · NBIX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · NBIX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
NBIX executive sell shares · NBIX board member insider trading · NBIX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 2, 2026 | Cooke Julie Chief Human Resources Officer | Option | 24,965 | $2.03M⚡ | Form 4 |
| Jun 2, 2026 | Cooke Julie Chief Human Resources Officer | Sale | 14,214 | $2.20M⚡ | Form 4 |
| Jun 2, 2026 | Cooke Julie Chief Human Resources Officer | Sale | 5,466 | $850K | Form 4 |
| Jun 2, 2026 | Cooke Julie Chief Human Resources Officer | Sale | 4,216 | $661K | Form 4 |
| Jun 2, 2026 | Cooke Julie Chief Human Resources Officer | Sale | 9,521 | $1.50M⚡ | Form 4 |
| Jun 2, 2026 | Cooke Julie Chief Human Resources Officer | Sale | 3,520 | $558K | Form 4 |
| Jun 2, 2026 | Keswani Sanjay Chandru Chief Medical Officer | Option | 3,212 | — | Form 4 |
| Jun 2, 2026 | Keswani Sanjay Chandru Chief Medical Officer | Other | 1,733 | $268K | Form 4 |
| Jun 1, 2026 | Onyia Jude Chief Scientific Officer | Option | 11,000 | $932K | Form 4 |
| Jun 1, 2026 | Onyia Jude Chief Scientific Officer | Sale | 11,000 | $1.76M⚡ | Form 4 |
| May 29, 2026 | Delaet Ingrid Chief Regulatory Officer | Option | 2,261 | $179K | Form 4 |
| May 29, 2026 | Delaet Ingrid Chief Regulatory Officer | Sale | 2,261 | $354K | Form 4 |
| May 27, 2026 | Onyia Jude Chief Scientific Officer | Option | 11,000 | $932K | Form 4 |
| May 27, 2026 | Onyia Jude Chief Scientific Officer | Sale | 11,000 | $1.71M⚡ | Form 4 |
| May 26, 2026 | Boyer David W. Chief Corp. Affairs Officer | Sale | 3,888 | $609K | Form 4 |
| May 21, 2026 | SHERWIN STEPHEN A Director | Option | 3,318 | — | Form 4 |
| May 21, 2026 | Sharp Shalini Director | Option | 1,659 | — | Form 4 |
| May 21, 2026 | RASTETTER WILLIAM H Director | Option | 3,318 | — | Form 4 |
| May 21, 2026 | POPS RICHARD F Director | Option | 3,318 | — | Form 4 |
| May 21, 2026 | POON CHRISTINE A Director | Option | 3,318 | — | Form 4 |
| May 21, 2026 | Norwalk Leslie V Director | Option | 1,659 | — | Form 4 |
| May 21, 2026 | MORROW GEORGE J Director | Option | 3,318 | — | Form 4 |
| May 21, 2026 | Mercier Johanna Director | Option | 3,318 | — | Form 4 |
| May 21, 2026 | LYONS GARY A Director | Option | 1,659 | — | Form 4 |
| May 19, 2026 | GORMAN KEVIN CHARLES Director | Option | 205,088 | $8.87M⚡ | Form 4 |
Cooke Julie
Chief Human Resources Officer
Date
Jun 2
Shares
24,965
Price
$81.49
Value
$2.03M ⚡
Cooke Julie
Chief Human Resources Officer
Date
Jun 2
Shares
14,214
Price
$154.83
Value
$2.20M ⚡
Cooke Julie
Chief Human Resources Officer
Date
Jun 2
Shares
5,466
Price
$155.46
Value
$850K
Cooke Julie
Chief Human Resources Officer
Date
Jun 2
Shares
4,216
Price
$156.77
Value
$661K
Cooke Julie
Chief Human Resources Officer
Date
Jun 2
Shares
9,521
Price
$157.62
Value
$1.50M ⚡
Cooke Julie
Chief Human Resources Officer
Date
Jun 2
Shares
3,520
Price
$158.59
Value
$558K
Keswani Sanjay Chandru
Chief Medical Officer
Date
Jun 2
Shares
3,212
Price
—
Value
—
Keswani Sanjay Chandru
Chief Medical Officer
Date
Jun 2
Shares
1,733
Price
$154.84
Value
$268K
Onyia Jude
Chief Scientific Officer
Date
Jun 1
Shares
11,000
Price
$84.74
Value
$932K
Onyia Jude
Chief Scientific Officer
Date
Jun 1
Shares
11,000
Price
$160.25
Value
$1.76M ⚡
Delaet Ingrid
Chief Regulatory Officer
Date
May 29
Shares
2,261
Price
$79.02
Value
$179K
Delaet Ingrid
Chief Regulatory Officer
Date
May 29
Shares
2,261
Price
$156.71
Value
$354K
Onyia Jude
Chief Scientific Officer
Date
May 27
Shares
11,000
Price
$84.74
Value
$932K
Onyia Jude
Chief Scientific Officer
Date
May 27
Shares
11,000
Price
$155.53
Value
$1.71M ⚡
Boyer David W.
Chief Corp. Affairs Officer
Date
May 26
Shares
3,888
Price
$156.64
Value
$609K
GORMAN KEVIN CHARLES
Director
Date
May 19
Shares
205,088
Price
$43.24
Value
$8.87M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About NBIX insider trading
NBIX insider trades
Neurocrine Biosciences, Inc. (NBIX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Boyer David W. (Chief Corp. Affairs Officer), ABERNETHY MATT (CFO), Gano Kyle (CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. NBIX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Neurocrine Biosciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
NBIX insider trading · 5 questionsThe insiders of Neurocrine Biosciences, Inc. (NBIX) include executives and directors such as Boyer David W. (Chief Corp. Affairs Officer), ABERNETHY MATT (CFO), Gano Kyle (CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026